IDEX Corporation (IEX) gains on deep Q3 earnings analysis
IDEX Corporation (IEX) gains after a broad Q3 beat, with adjusted EPS and revenue topping estimates, orders strengthening across all segments, and margins improving. The deeper story is the raised 2026 outlook, record Health and Science orders, and continued momentum in data center, semiconductor, and defense markets.
IDEX Corporation (NYSE: IEX) delivered a solid third-quarter beat, topping estimates on adjusted EPS and revenue while posting stronger orders across all three segments. Management also raised its 2026 outlook, signaling that demand in data centers, semiconductors, space and defense, and water is translating into better growth and profitability for investors.
IDEX Corporation (IEX) gains 1.88% to $237.59 after the industrial machinery company beat third-quarter estimates on adjusted EPS and revenue. The $2.33 adjusted EPS result, stronger orders, and raised 2026 outlook give the stock a firm earnings-day foundation.
Adjusted EPS reached $2.33, ahead of the $2.24 estimate. Revenue totaled $0.95B, above the $0.93B consensus.
Health and Science Technologies led segment growth with organic sales up 13% and orders up 21% to $468M.
Organic orders rose 13% year over year to nearly $1B, with growth across all three segments and book-to-bill above 1 times.
IDEX raised 2026 guidance for organic growth to 6.5% to 6.8%, adjusted EBITDA margin to 27.1% to 27.3%, and adjusted EPS to $8.91 to $8.96.
CEO Eric D. Ashleman emphasized data centers, semiconductors, space and defense, and water as key growth markets.
Analyst positioning remains constructive. The consensus is Buy, with 15 Buy ratings and 14 Holds. Oppenheimer raised its target to $275 from $270 while keeping an Outperform rating.
The third quarter delivered a clean beat across the main operating measures. Revenue reached $0.95B, compared with $0.92B in the second quarter and $0.89B in the first quarter. Net income was $0.14B in Q3, matching Q2 and exceeding the $0.12B recorded in Q1.
Adjusted EPS rose to $2.33 from $2.32 in Q2. The company has also exceeded adjusted EPS estimates in each of the last five reported quarters: $2.33 versus $2.24 in Q3, $2.32 versus $2.11 in Q2, $2.00 versus $1.77 in Q1, $2.10 versus $2.04 in Q4 2025, and $2.03 versus $1.93 in Q3 2025. That pattern gives the current beat more weight than a one-quarter surprise.
Profitability improved at both the consolidated and segment levels. Adjusted gross margin expanded 70 basis points to 45.2%. Adjusted EBITDA margin increased 50 basis points year over year to 27.8%, above the company’s 27% to 27.5% guidance range.
Health and Science Technologies was the main growth engine. Organic sales increased 13%, while adjusted EBITDA margin expanded 110 basis points to 28.8%. Semiconductor original equipment demand, semiconductor consumables, data center applications, and space and defense drove the segment. Orders grew 21% to $468M, a third-quarter record.
Fluid and Metering Technologies added steadier growth. Organic sales increased 4%, and orders rose 11% to $349M. The segment’s adjusted EBITDA margin reached 33.9%, up 20 basis points. Semiconductor activity and municipal water led the quarter, while chemical valves and agriculture still declined year over year despite sequential improvement.
Fire and Safety Diversified Products posted 6% organic sales growth. All three businesses grew, led by BAND-IT’s exposure to aerospace and defense. Dispensing also returned to growth as comparisons became easier. Adjusted EBITDA margin expanded 140 basis points to 28.5%, the strongest margin improvement among the three segments.
The annual segment mix reinforces the importance of HST. In 2025, HST generated $1.4955B of revenue, compared with $1.224B for FMT and $745.3M for FSDP. The current quarter shows HST accelerating while the two industrial segments broaden their recovery.
Cash flow added another positive signal. Free cash flow reached $214M, equal to 124% conversion. Liquidity exceeded $1.2B, while gross leverage improved to 1.8 times from 2.1 times a year earlier. IDEX is funding capital investment while preserving room for balance-sheet flexibility.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
At 3:30 PM ET on Oct. 28, IEX traded at $237.59, up 1.88% during the regular session. Volume reached 1,132,446 shares against an average of 648,873. The gain reflects a favorable response to the earnings beat and the higher full-year outlook.
Analyst action around IDEX has leaned positive. Oppenheimer analyst Bryan Blair raised his price target to $275 from $270 on Oct. 21 and kept an Outperform rating. RBC Capital analyst Jeffrey Reive raised his target to $285 from $280 on Oct. 14, also with an Outperform rating.
Earlier moves were constructive as well. Mizuho upgraded IEX from Neutral to Outperform on Aug. 12 and lifted its target from $210 to $280. Argus raised its target from $250 to $260 while maintaining Buy, and DA Davidson moved its Neutral target from $230 to $240. These actions show analysts entering the quarter with a rising view of IDEX’s growth profile.
The valuation debate remains separate from the operating result. A company can deliver a strong quarter and still face a demanding share price. For IEX, the raised EPS range and stronger order book give analysts new operating evidence to support the higher targets already appearing across the coverage list.
CEO Eric D. Ashleman framed the quarter as the result of deliberate investment in markets with stronger demand and better technical economics. Data centers, semiconductors, space and defense, and water all contributed to the growth narrative. He also highlighted IDEX’s ability to shift technology and resources between applications.
"Our ability to tune our solutions laterally and quickly to faster growing verticals is a distinct competitive advantage." - Eric D. Ashleman, CEO, IDEX Corporation earnings call
That strategy showed up in the quarter. Ashleman pointed to porous metal filtration moving from legacy energy uses into semiconductor manufacturing, electroforming technology moving into data center optical switching, and laser etching moving into space applications. In plain English, IDEX is reusing specialized engineering skills where customer demand is growing faster.
"It has proven stubborn, and elevated energy prices continue to push input costs higher but the IDEX model is built to handle this." - Eric D. Ashleman, CEO, IDEX Corporation earnings call
Ashleman said targeted pricing and productivity kept price-cost performance positive. That matters because the company’s components often represent a small share of a customer’s total system cost. IDEX can therefore defend pricing when its products perform mission-critical functions, even as energy costs rise.
CFO Sean Gillen focused on the gap between reported performance and the prior operating plan. His comments showed that the quarter did not merely meet the plan. It exceeded the company’s own sales, margin, and EPS ranges.
"Organic revenue grew 8%, above our 5% to 7% range, with notable strength again in HST and solid contribution from FMT and FSDP." - Sean Gillen, CFO, IDEX Corporation earnings call
"Adjusted EBITDA margin of 27.8% was above our 27% to 27.5% range and adjusted EPS of $2.33 was above our $2.20 to $2.25 range." - Sean Gillen, CFO, IDEX Corporation earnings call
Gillen’s updated outlook raises the bar for the fourth quarter. IDEX now expects 2026 organic growth of 6.5% to 6.8%, up from 5% to 6%. The adjusted EBITDA margin forecast moved to 27.1% to 27.3% from 26.8% to 27.2%, while adjusted EPS increased to $8.91 to $8.96 from $8.70 to $8.85.
Bottom Line
IDEX Corporation’s Q3 results combine a double beat, stronger orders, expanding margins, and higher 2026 guidance. The strongest evidence supports the growth catalyst case, while the next investment debate centers on whether HST momentum and the industrial recovery can sustain the raised outlook.
Yes. IDEX reported adjusted EPS of $2.33 versus the $2.24 estimate, and revenue of $0.95 billion versus the $0.93 billion consensus.
+Why did IDEX stock rise after earnings?
The stock rose because IDEX beat third-quarter estimates, posted stronger organic orders, and raised its 2026 guidance. Investors also reacted positively to margin expansion and the company’s improving free cash flow and leverage profile.
+What did IDEX say about 2026 guidance?
IDEX raised its 2026 organic growth outlook to 6.5% to 6.8%, adjusted EBITDA margin to 27.1% to 27.3%, and adjusted EPS to $8.91 to $8.96. The higher outlook suggests management sees continued demand strength and operating leverage ahead.
+Which IDEX segment performed best in Q3?
Health and Science Technologies was the standout segment, with organic sales up 13% and orders up 21% to a record $468 million. The segment was helped by semiconductor, data center, space, and defense demand.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on IEX?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
